Related Experiment Video
Updated: Jul 8, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
A new risk factor for coronary artery disease can be detected by an ApoA1 mAb-based assay
Hui Ding1, Yin Wang2, Yan Zhang3
1Department of Laboratory Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.
Insights
A new apolipoprotein A1 (ApoA1) monoclonal antibody (mAb) assay identifies a high-density lipoprotein (HDL) subclass linked to coronary artery disease (CAD). This assay aids in improving CAD risk assessment.
Area of Science:
- Biochemistry
- Immunology
- Cardiovascular Medicine
Background:
- Coronary artery disease (CAD) poses a significant global health challenge.
- Biomarkers for early and accurate CAD detection are crucial for effective management.
- Apolipoprotein A1 (ApoA1) is a key component of high-density lipoprotein (HDL) cholesterol.
Purpose of the Study:
- To identify an apolipoprotein A1 (ApoA1) monoclonal antibody (mAb) associated with coronary artery disease (CAD).
- To evaluate the diagnostic utility of an assay utilizing this ApoA1 mAb for CAD.
- To explore the relationship between ApoA1 subclasses and CAD risk.
Main Methods:
- Recruited 180 CAD patients and 199 healthy controls.
- Employed Spearman's rank correlation and logistic regression for association analysis.
- Utilized Receiver Operating Characteristic (ROC) curve analysis to assess diagnostic accuracy.
Main Results:
- ApoA1 mAb measurements showed a significant positive correlation with CAD (r=0.243, P<0.01).
- The ApoA1 mAb assay demonstrated an area under the ROC curve of 0.704 in patients with normal HDL-C.
- ApoA1 values from the mAb assay positively impacted CAD risk assessment.
Conclusions:
- An ApoA1 mAb-based assay can identify an HDL subclass positively associated with CAD.
- This assay offers potential for enhanced and reappraised CAD risk stratification.
- The findings suggest a novel approach to improving cardiovascular risk assessment.
Background:
This study aimed to find coronary artery disease (CAD) related apolipoprotein A1 (ApoA1) monoclonal antibody (mAb) and to evaluate the diagnostic value of the assay based on it.
Methods:
Patients with CAD diagnosed by coronary angiography (disease group, n = 180) and healthy subjects (control group, n = 199) were recruited. The correlation between methods and CAD were evaluated by Spearman's rank correlation coefficients. Receiver operating characteristic (ROC) curve analysis was used to evaluate the auxiliary diagnostic value of methods for CAD. Odds ratios (ORs) of the test results in CAD were estimated using logistic regression analysis.
Results:
Measurements from an ApoA1 mAb were found significantly positively correlated with CAD (r = 0.243, P < 0.01), unlike the measurements from the ApoA1 pAb were negatively correlated with CAD (r = -0.341, P < 0.001). The areas under the ROC curve of the ApoA1 mAb and pAb measurements were 0.704 and 0.563, respectively, in patients with normal HDL-C levels. ApoA1 values from the mAb assay had a significant positive impact on CAD risk.
Conclusion:
An ApoA1 mAb-based assay can distinguish a high-density lipoprotein (HDL) subclass positively related to CAD, which can be used to improve and reappraise CAD risk assessment.
